Straits Times Index
3,292.69 +10.64 (+0.32%) S&P 500
5,063.65 +27.96 (+0.56%) Dow
38,170.42 +354.50 (+0.94%) Nasdaq
15,802.95 +145.13 (+0.93%) Bitcoin USD
58,001.52 -1,968.07 (-3.28%) CMC Crypto 200
1,218.98 -120.09 (-8.95%)
Intellia Therapeutics, Inc. (NTLA)
| Previous close | 21.40 |
| Open | 21.33 |
| Bid | 22.95 x 100 |
| Ask | 23.11 x 100 |
| Day's range | 21.33 - 23.56 |
| 52-week range | 19.37 - 47.48 |
| Volume | |
| Avg. volume | 1,486,813 |
| Market cap | 2.223B |
| Beta (5Y monthly) | 1.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.42 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 70.96 |
GlobeNewswireIntellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to be completely attack free through the latest follow-upIntellia to host investor webcast on Monday, June 3, at 8 a.m. ET CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the acceptance of an oral pre
ZacksIntellia (NTLA) to Report Q1 Earnings: What's in the Cards?
On Intellia's (NTLA) first-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.
ZacksEarnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline
Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
